Fundamental Analysis of VIRACTA THERAPEUTICS INC(NASDAQ:VIRX) stock

Fundamental Rating

Overall VIRX gets a fundamental rating of 0 out of 10. We evaluated VIRX against 565 industry peers in the Biotechnology industry. VIRX has a bad profitability rating. Also its financial health evaluation is rather negative. VIRX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

VIRX had negative earnings in the past year.

VIRX had a negative operating cash flow in the past year.

In the past 5 years VIRX always reported negative net income.

In the past 5 years VIRX always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -197.14%, VIRX is doing worse than 89.91% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-197.14%
ROE	N/A
ROIC	N/A

ROA(3y)-82.33%

ROA(5y)-80.57%

ROE(3y)-160.27%

ROE(5y)-134.85%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VIRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for VIRX has been increased compared to 1 year ago.

VIRX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for VIRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -26.13, we must say that VIRX is in the distress zone and has some risk of bankruptcy.

VIRX has a worse Altman-Z score (-26.13) than 89.91% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-26.13

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.76, VIRX is doing worse than 90.62% of the companies in the same industry.

A Quick Ratio of 0.76 indicates that VIRX may have some problems paying its short term obligations.

The Quick ratio of VIRX (0.76) is worse than 90.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.76
Quick Ratio	0.76

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.29% over the past year.

EPS 1Y (TTM)11.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.18%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VIRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.15% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y38.18%

EPS Next 2Y31.22%

EPS Next 3Y19.14%

EPS Next 5Y14.15%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VIRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year VIRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VIRX's earnings are expected to grow with 19.14% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.22%

EPS Next 3Y19.14%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VIRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIRACTA THERAPEUTICS INC

NASDAQ:VIRX (12/20/2024, 8:00:01 PM)

After market: 0.2274 +0.02 (+8.29%)

0.21

0 (-1.87%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2024-11-13/bmo

Earnings (Next)N/A N/A

Inst Owners48.83%

Inst Owner Change-39.3%

Ins Owners2.41%

Ins Owner Change0.52%

Market Cap8.35M

Analysts80

Price Target2.55 (1114.29%)

Short Float %4.08%

Short Ratio0.59

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)12.86%

Min EPS beat(2)-8.04%

Max EPS beat(2)33.76%

EPS beat(4)2

Avg EPS beat(4)12.76%

Min EPS beat(4)-10.69%

Max EPS beat(4)36.03%

EPS beat(8)3

Avg EPS beat(8)8.46%

EPS beat(12)6

Avg EPS beat(12)5.61%

EPS beat(16)8

Avg EPS beat(16)20.36%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-28.57%

PT rev (3m)-31.82%

EPS NQ rev (1m)0%

EPS NQ rev (3m)34.27%

EPS NY rev (1m)8.05%

EPS NY rev (3m)8.05%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.1

EYN/A

EPS(NY)-0.37

Fwd EYN/A

FCF(TTM)-0.88

FCFYN/A

OCF(TTM)-0.88

OCFYN/A

SpS0

BVpS-0.17

TBVpS-0.17

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-197.14%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-82.33%

ROA(5y)-80.57%

ROE(3y)-160.27%

ROE(5y)-134.85%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0.46%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.76
Quick Ratio	0.76
Altman-Z	-26.13

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)63.58%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)11.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.18%

EPS Next Y38.18%

EPS Next 2Y31.22%

EPS Next 3Y19.14%

EPS Next 5Y14.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y3.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y0.12%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-0.09%

OCF growth 3YN/A

OCF growth 5YN/A

VIRACTA THERAPEUTICS INC (VIRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens